Publications by authors named "Sudhir Agrawal"

Claim this Profile
C
Considerations for Creating the Next Generation of RNA Therapeutics: Oligonucleotide Chemistry and Innate Immune Responses to Nucleic Acids.
Sudhir Agrawal

Nucleic Acid Ther· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing antisense oligonucleotides for a mutation-induced, ultra-rare neurological disorder using patient-derived cellular models.
Luis A Williams, David J Gerber, Amy Elder, Wei Chou Tseng, Valeriya Baru, Sudhir Agrawal

Mol Ther Nucleic Acids· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Introduction and History of the Chemistry of Nucleic Acids Therapeutics.
Michael J Gait, Sudhir Agrawal

Methods Mol Biol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Suppression of Kv3.3 channels by antisense oligonucleotides reverses biochemical effects and motor impairment in spinocerebellar ataxia type 13 mice.
Yalan Zhang, Imran H Quraishi, Heather McClure, Luis A Williams, YungChih Cheng, Sudhir Agrawal

FASEB J· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.
Cara Haymaker, Daniel H Johnson, Ravi Murthy, Salah-Eddine Bentebibel, Marc I Uemura, Sudhir Agrawal

Cancer Discov· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey.
Sudhir Agrawal

Biomedicines· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RNA Therapeutics Are Stepping Out of the Maze.
Sudhir Agrawal

Trends Mol Med· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors.
Sudhir Agrawal, Ekambar R Kandimalla

Immunooncol Technol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integration of 3D printing with dosage forms: A new perspective for modern healthcare.
Shende Pravin, Agrawal Sudhir

Biomed Pharmacother· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Daqing Wang, Wayne Jiang, Fugang Zhu, Xianzhi Mao, Sudhir Agrawal

Int J Oncol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis.
Sabine M J Welten, Rob C M de Jong, Anouk Wezel, Margreet R de Vries, Martin C Boonstra, Sudhir Agrawal

Atherosclerosis· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of Mef2a Enhances Neovascularization via Post-transcriptional Regulation of 14q32 MicroRNAs miR-329 and miR-494.
Sabine M J Welten, Margreet R de Vries, Erna A B Peters, Sudhir Agrawal, Paul H A Quax

Mol Ther Nucleic Acids· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
RAGE Enhances TLR Responses through Binding and Internalization of RNA.
Damien Bertheloot, Allison L Naumovski, Pia Langhoff, Gabor L Horvath, Tengchuan Jin, Sudhir Agrawal

J Immunol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cutting edge: the UNC93B1 tyrosine-based motif regulates trafficking and TLR responses via separate mechanisms.
Karin Pelka, Kshiti Phulphagar, Jana Zimmermann, Rainer Stahl, Jonathan L Schmid-Burgk, Sudhir Agrawal

J Immunol· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Toll-like receptors in the pathogenesis of dystrophin-deficient skeletal and heart muscle.
Andrea Henriques-Pons, Qing Yu, Sree Rayavarapu, Tatiana V Cohen, Beryl Ampong, Sudhir Agrawal

Hum Mol Genet· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel antagonist of Toll-like receptors 7, 8 and 9 suppresses lupus disease-associated parameters in NZBW/F1 mice.
Fu-Gang Zhu, Weiwen Jiang, Lakshmi Bhagat, Daqing Wang, Dong Yu, Sudhir Agrawal

Autoimmunity· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis.
Weiwen Jiang, Fu-Gang Zhu, Lakshmi Bhagat, Dong Yu, Jimmy X Tang, Sudhir Agrawal

J Invest Dermatol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9.
Ekambar R Kandimalla, Lakshmi Bhagat, Daqing Wang, Dong Yu, Tim Sullivan, Sudhir Agrawal

Nucleic Acids Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of synthetic oligoribonucleotide-based agonists of Toll-like receptor 3 and their immune response profiles in vitro and in vivo.
Tao Lan, Daqing Wang, Lakshmi Bhagat, Victoria J Philbin, Dong Yu, Sudhir Agrawal

Org Biomol Chem· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune-Stimulatory Dinucleotide at the 5'-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses.
Mallikarjuna R Putta, Lakshmi Bhagat, Daqing Wang, Fu-Gang Zhu, Ekambar R Kandimalla, Sudhir Agrawal

ACS Med Chem Lett· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy.
Huagang Zhang, Laibin Liu, Dong Yu, Ekambar R Kandimalla, Hui Bin Sun, Sudhir Agrawal

PLoS One· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome.
Subhrajit Saha, Payel Bhanja, Laibin Liu, Alan A Alfieri, Dong Yu, Sudhir Agrawal

PLoS One· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
Ekambar R Kandimalla, Mary Struthers, Andrew J Bett, Thomas Wisniewski, Sheri A Dubey, Sudhir Agrawal

Cell Immunol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
Roberta Rosa, Davide Melisi, Vincenzo Damiano, Roberto Bianco, Sonia Garofalo, Sudhir Agrawal

Clin Cancer Res· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel oligonucleotides containing two 3'-ends complementary to target mRNA show optimal gene-silencing activity.
Lakshmi Bhagat, Mallikarjuna Reddy Putta, Daqing Wang, Dong Yu, Tao Lan, Sudhir Agrawal

J Med Chem· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis